Antibiotic Stewardship in Acute Rhinosinusitis

Diagnostic Considerations

• A new onset of fever and upper‑respiratory symptoms occurring ≥2 weeks after completing a 10‑day course of amoxicillin‑clavulanate for sinusitis represents a separate viral illness rather than treatment failure of the prior bacterial sinusitis【1】.
• The presence of a symptom‑free interval of about two weeks strongly suggests a viral upper‑respiratory infection, because bacterial sinusitis would typically persist or recur sooner【2】.
• According to the American College of Physicians and CDC guidelines, antibiotics for acute rhinosinusitis are warranted only when any one of the following bacterial criteria is met:

When Antibiotics Are Indicated

• Prescribe antibiotics only if the patient exhibits one of the three bacterial patterns listed above【1】.

First‑Line (Supportive) Management

• Supportive care alone is recommended for the majority of adults with acute rhinosinusitis【5】.
• The number needed to treat (NNT) with antibiotics to achieve one additional clinical benefit is 18, whereas the number needed to harm (NNH) for adverse effects is 8, indicating limited benefit and higher risk of harm【6】.
• Symptomatic therapies that can be offered include:

Watchful‑Waiting Strategy

• The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) endorses watchful waiting without antibiotics as the initial approach for uncomplicated acute bacterial rhinosinusitis, regardless of severity【5】.
• Acute rhinosinusitis is generally self‑limited and often resolves without antibiotics even when a bacterial etiology is present【5】.

Referral Recommendations

• Refer to an otolaryngologist, infectious‑disease specialist, or allergist if any of the following occurs:

Risks of Unnecessary Antibiotic Use

• Prescribing antibiotics in the setting of a recent viral illness carries a 40–44 % risk of diarrhea and a 7–8 % risk of severe diarrhea, with no clinical benefit for the current viral syndrome【1】.
• Inappropriate use of amoxicillin‑clavulanate for viral infections contributes to antibiotic resistance and exposes patients to avoidable adverse effects such as diarrhea and yeast infections【1】.

Antibiotic Use in Acute Rhinosinusitis: Evidence‑Based Recommendations

Criteria for Initiating Antibiotics

• Antibiotics should be prescribed only when one of the three bacterial patterns is present: (1) persistent symptoms > 10 days without improvement; (2) severe illness with fever > 39 °C plus purulent nasal discharge or facial pain for ≥3 consecutive days at onset; or (3) “double sickening,” i.e., worsening after initial improvement within the first 5 days of a typical viral course. 7

Risks Associated with Antibiotic Therapy

• In patients with viral acute rhinosinusitis, amoxicillin‑clavulanate carries a 40–44 % risk of any diarrhea and a 7–8 % risk of severe diarrhea, providing no clinical benefit for viral infections. 7
• The number needed to treat (NNT) to achieve one additional clinical benefit in acute rhinosinusitis is 18, whereas the number needed to harm (NNH) for adverse effects is 8, indicating that harms outweigh benefits in most cases. 7
• Inappropriate antibiotic use contributes to antimicrobial resistance and increases the likelihood of adverse events such as yeast infections and gastrointestinal complications. 7

Recommended Management (Supportive Care)

• Use systemic or topical decongestants to relieve nasal congestion. 7
• Perform saline nasal irrigation to aid clearance of secretions. 7
• Apply intranasal corticosteroids to reduce mucosal inflammation. 7
• Consider mucolytics if secretions are thick. 7
• Provide antipyretics (e.g., acetaminophen or ibuprofen) for fever or discomfort. 7
• Offer analgesics for ear pressure or facial discomfort. 7

Indicators for Escalation of Care

• Seek medical evaluation if symptoms persist beyond 10 days without any improvement. 7
• Seek care if a high fever > 39 °C develops together with severe purulent nasal discharge or facial pain. 7
• Seek care if there is significant worsening after initial improvement (“double sickening”). 7
• Seek care for signs of serious illness such as severe headache, visual changes, neck stiffness, altered mental status, or systemic infection. 7
• Seek care if clinical condition deteriorates despite appropriate supportive measures. 7

Natural Course and Clinical Signs

• Acute rhinosinusitis is generally self‑limited, resolving within 7–10 days even without antibiotics, regardless of viral or bacterial etiology. 7
• The presence of purulent (colored) nasal discharge or sputum does not reliably indicate bacterial infection; viral infections frequently produce purulent secretions. 7
• Most viral upper respiratory infections improve within 5–7 days, although cough may linger for 2–3 weeks. 7

Guideline Recommendations for Acute Sinusitis Management in Older Adults

Antibiotic Use Criteria

• In geriatric patients with acute sinusitis, antimicrobial therapy should be reserved for those who meet strict bacterial criteria: (1) symptoms persisting > 10 days without improvement, (2) severe onset with fever > 39 °C plus purulent nasal discharge or facial pain for ≥ 3 consecutive days, or (3) “double sickening” (worsening after initial improvement within the first 5 days of a typical viral course) — all other patients receive symptomatic care only. 8

First‑Line Symptomatic Therapies

• Analgesics (acetaminophen or ibuprofen) are recommended for facial pain and headache; NSAIDs should be used cautiously in older adults because of common comorbidities (renal, cardiovascular, gastrointestinal). 9
• Nasal saline irrigation—especially higher‑volume irrigations—provides symptom relief and has minimal adverse effects. 9
• Topical intranasal corticosteroids produce modest symptom improvement; the number needed to treat (NNT) is 11–13, with longer courses and higher doses yielding greater benefit. 9
• Topical oxymetazoline may be used for up to 3–5 days to avoid rebound congestion (rhinitis medicamentosa). 9

Interventions to Avoid in Older Adults

• First‑generation antihistamines should be avoided; they show no benefit for nasal obstruction, rhinorrhea, or sneezing in this population. 9
• Oral phenylephrine is discouraged by the FDA advisory committee after multiple randomized trials demonstrated lack of efficacy. 9
• Pseudoephedrine carries cardiovascular risks (elevated blood pressure and heart rate) in the elderly and lacks recent supportive evidence. 9
• Guaifenesin and dextromethorphan have no demonstrated clinical efficacy for acute sinusitis in older patients. 9

Special Considerations for the Elderly

• NSAIDs may be contraindicated or require dose adjustment in patients with renal disease, cardiovascular disease, or a history of gastrointestinal bleeding. 9
• Decongestants (including topical agents) pose heightened cardiovascular risk in older adults with hypertension or cardiac disease and should be used only after careful risk‑benefit assessment. 9